Synthetic inhibition of the SUMO pathway by targeting the SAE1 component via TAK-981 compound impairs tumor growth and chemosensitizers embryonal and alveolar rhabdomyosarcoma cell lines.
Silvia Codenotti, Volker Martin Lauschke, Emma V. Casella, Daniel C. Andersson, Alessandro Fanzani, Stefano Gastaldello
This study shows that TAK-981, a SUMO inhibitor targeting SAE1, reduces RMS cell growth and enhances chemotherapy effectiveness without increasing radiosensitivity.
bioRxiv · Jan 15, 2025 · PreprintCancer Biology